GSK (LSE:GSK) has received regulatory approval in China for Exdensur (depemokimab) as an add-on treatment for adults with chronic rhinosinusitis with nasal polyps (CRSwNP) whose condition remains uncontrolled despite systemic corticosteroids and/or surgical intervention. The therapy becomes the first ultra-long-acting biologic approved for this indication in the Chinese market, reinforcing GSK’s strategy to strengthen its presence in respiratory biologics within a key growth region.
The approval follows results from the Phase III ANCHOR clinical trial, which demonstrated statistically significant improvements in nasal polyp size and nasal obstruction with a twice-yearly dosing regimen. The treatment’s safety profile was comparable to placebo when administered alongside standard of care. Exdensur has already received approvals in China for severe asthma and in multiple markets globally for both asthma and CRSwNP. The expanded regulatory clearance further strengthens GSK’s position in therapies targeting type 2 inflammation-driven respiratory diseases and broadens treatment options for patients suffering from persistent symptoms.
The company’s outlook remains supported by strong profitability and improving underlying financial performance, alongside constructive guidance for 2026 and continued pipeline progress. Valuation appears reasonable and includes a modest dividend yield. However, near-term upside may be tempered by technical signals suggesting overbought conditions and ongoing considerations around balance-sheet dynamics and earnings consistency.
More about GSK
GSK is a global biopharmaceutical company focused on preventing and treating disease through vaccines, specialty medicines and advanced biologics. The group has a strong focus on respiratory and immunology conditions, developing targeted therapies and inhaled medicines designed to address the underlying mechanisms of diseases such as asthma, chronic obstructive pulmonary disease (COPD) and other inflammatory disorders.
Leave a Reply